Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes

被引:91
作者
Ho, PL
Chan, WM
Tsang, KWT
Wong, SSY
Young, K
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Div Infect Dis, Pokfulam, Hong Kong, Peoples R China
[2] Yan Chai Hosp, Intens Care Unit, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam, Hong Kong, Peoples R China
[4] Univ Hong Kong, Queen Mary Hosp, Intens Care Unit, Pokfulam, Hong Kong, Peoples R China
关键词
D O I
10.1080/00365540210147516
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A case-control study was conducted in order to identify the risk factors associated with bloodstream infection caused by Escherichia coli producing extended-spectrum beta-lactamase (ESBL) and to determine the outcomes of infected patients. Risk factors associated with ESBL production, according to univariate analysis, included a history of recent hospitalization [odds ratio (OR) 4.3, 95% confidence interval (CI) 2.1-8.9; p < 0.001], severe underlying diseases (OR 15, 95% CI 4.4-51.5; p < 0.001), prior exposure to urinary catheters (OR 8.3, 95% CI 3.2-21.7; p < 0.001) and nosocomial (OR 14.1, 95% CI 6.1-32.8; p < 0.001) or urinary (OR 3.6, 95% CI 1.7-7.4; p < 0.001) origin of the bacteria. Multivariate analysis revealed that severe underlying diseases (OR 31.2, 95% CI 6.7-144; p < 0.001) and nosocomial (OR 16.5, 95% CI 5.6-49; p < 0.001) and urinary origins (OR 7.8, 95% CI 2.6-23.8; p < 0.001) of the bacteria were independently associated with ESBL production in bacteremic E. coli. Crude mortality in case patients was more than twice as high as that in controls (p = 0.04). Production of ESBL increased the risk of inappropriate initial therapy (OR 95.6, 95% CI 27.4-334.2; p < 0.001). Treatment failed in 4/7 case patients treated with ceftazidime to which the isolate was susceptible in vitro. Our findings have implications for the choice of empirical therapy in nosocomial urinary tract infection.
引用
收藏
页码:567 / 573
页数:7
相关论文
共 28 条
  • [1] Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998
    Babini, GS
    Livermore, DM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) : 183 - 189
  • [2] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [3] CEFTRIAXONE-SULBACTAM COMBINATION IN RABBIT ENDOCARDITIS CAUSED BY A STRAIN OF KLEBSIELLA-PNEUMONIAE PRODUCING EXTENDED-BROAD-SPECTRUM TEM-3 BETA-LACTAMASE
    CARON, F
    GUTMANN, L
    BURE, A
    PANGON, B
    VALLOIS, JM
    PECHINOT, A
    CARBON, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) : 2070 - 2074
  • [4] Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen
    Cormican, MG
    Marshall, SA
    Jones, RN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (08) : 1880 - 1884
  • [5] A CASE-CONTROL STUDY OF AN OUTBREAK OF INFECTIONS CAUSED BY KLEBSIELLA-PNEUMONIAE STRAINS PRODUCING CTX-1 (TEM-3) BETA-LACTAMASE
    DECHAMPS, C
    ROUBY, D
    GUELON, D
    SIROT, J
    SIROT, D
    BEYTOUT, D
    GOURGAND, JM
    [J]. JOURNAL OF HOSPITAL INFECTION, 1991, 18 (01) : 5 - 13
  • [6] Clinical and bacteriologic epidemiology of extended-spectrum β-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit
    Decré, D
    Gachot, B
    Lucet, JC
    Arlet, G
    Bergogne-Bérézin, E
    Régnier, B
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) : 834 - 844
  • [7] Diekema DJ, 1999, CLIN INFECT DIS, V29, P595, DOI 10.1086/598640
  • [8] Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center
    Emery, CL
    Weymouth, LA
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (08) : 2061 - 2067
  • [9] ACTIVITY OF SULBACTAM IN COMBINATION WITH CEFTRIAXONE INVITRO AND IN EXPERIMENTAL ENDOCARDITIS CAUSED BY ESCHERICHIA-COLI PRODUCING SHV-2-LIKE BETA-LACTAMASE
    FANTIN, B
    PANGON, B
    POTEL, G
    CARON, F
    VALLEE, E
    VALLOIS, JM
    MOHLER, J
    BURE, A
    PHILIPPON, A
    CARBON, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) : 581 - 586
  • [10] Gram-negative bacteremia in non-neutropenic patients: A 3-year review
    Gikas, A
    Samonis, G
    Christidou, A
    Papadakis, J
    Kofteridis, D
    Tselentis, Y
    Tsaparas, N
    [J]. INFECTION, 1998, 26 (03) : 155 - 159